Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07565675

The BALANCE Study - Improving Glucose Control Through Prebiotic Gut Health Drink in Postmenopausal Women

The menopausal transition is associated with a decline in oestrogen levels, contributing to adverse metabolic changes including increased central adiposity, systemic inflammation, and insulin resistance. These changes are linked to a higher risk of developing type 2 diabetes in postmenopausal women.

Recent evidence suggests that the gut microbiota plays an important role in metabolic regulation and glucose homeostasis. Menopause-related hormonal changes may alter the composition and function of the gut microbiome, with downstream effects on insulin sensitivity. Additionally, certain gut bacteria (i.e., Bifidobacterium species) regulate circulating oestrogen via β-glucuronidase activity, highlighting a potential interaction between microbial composition and hormonal balance. Observational findings support associations between menopausal stage, gut microbiota alterations, and insulin homeostasis.

Prebiotics are non-digestible compounds that selectively stimulate beneficial gut bacteria and may improve metabolic outcomes. Modulation of the gut microbiota through prebiotic supplementation represents a promising non-pharmacological strategy to improve glucose control. Multiple studies have demonstrated that inulin (a common prebiotic) can improve glucose regulation and aid weight loss in individuals with obesity, prediabetes, or type 2 diabetes. However, to date, no randomised controlled trials have specifically investigated prebiotic supplementation in postmenopausal women with prediabetes using dynamic measures such as the Oral Glucose Tolerance Test (OGTT).

The present study aims to investigate the effect of daily consumption of an inulin-containing prebiotic gut health drink (ió everyday) on glucose control in postmenopausal women with prediabetes. The primary objective is to determine whether the intervention improves glycaemic control. Secondary objectives include exploration of changes in metabolic markers and assessment of the role of the gut microbiota in mediating these effects.

It is hypothesised that consumption of ió everyday will improve glucose control in prediabetic women who have recently undergone menopause. This hypothesis is supported by evidence demonstrating that inulin and soluble corn fibre can improve glucose regulation and support weight management in individuals with obesity, prediabetes, or type 2 diabetes, as well as findings from a previous study (Ethics Ref ID: LSC 23/383), which demonstrated that one month of ió everyday consumption significantly reduced fasting glucose, with a trend towards weight reduction and no reported adverse effects.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Menopause Body Weight Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

45 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Health Sciences Research Centre, Life Sciences Department, University of Roehampton

London, UK, SW15 4JD, United Kingdom

About this study

This is a 4-week, randomised, placebo-controlled pilot trial investigating the effects of a gut ió everyday on glucose control in postmenopausal women with prediabetes. Participants will be allocated to either an intervention or placebo group. The intervention consists of ió everyday consumed daily for 4 weeks (one sachet daily in week 1, increasing to two sachets daily in weeks 2-4, taken with meals). The placebo group will receive matched sachets without inulin but equivalent in energy content. This is an investigator-initiated, randomised, placebo-controlled pilot study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

:

  • Female, aged 45-60 years
  • Post-menopausal (no menstrual period for ≥12 months)
  • No serious long-term medical conditions
  • Living in the UK
  • Able to read English and provide electronic informed consent
  • Willing and able to comply with study procedures, including dietary intervention and sample collection
  • Willing to provide stool samples at specified time points
  • BMI ≥25 kg/m² with one of the following:
  • Impaired glucose tolerance (7.8-11.0 mmol/L at 2-hour OGTT), or
  • Impaired fasting glucose (5.6-6.9 mmol/L), or
  • HbA1c 5.7%-6.4%
  • No intentional dieting within the past month
  • No >5% body weight loss in the past year
  • No changes in physical activity in the past 2-4 weeks and no intention to change during the study

Exclusion criteria

  • Significant gastrointestinal disease (e.g., inflammatory bowel disease, coeliac disease) or other major medical conditions affecting gut microbiota or study safety
  • Immunocompromised status or other serious chronic illness
  • Use of antibiotics within the past 2-3 months
  • Regular use of probiotics or prebiotics within the past 4 weeks
  • Use of medications or special diets that significantly affect gut microbiota (e.g., chronic laxatives, immunosuppressants)
  • Known allergies or intolerances to components of the prebiotic formulation
  • Participation in another interventional clinical trial within the past 3 months

Treatment and study plan

ió everyday (a prebiotic- enriched gut health drink containing inulin)

Dietary Supplement

Participants will consume the equivalent placebo comparator for 4 weeks. Each sachet contains 5 g inulin of maltodextrin. Participants will consume one sachet daily in week 1 to allow acclimatisation, increasing to two sachets daily in weeks 2-4. Sachets are diluted in 500 mL of water and consumed with lunch and dinner.

Placebo Comparator

Dietary Supplement

Participants will consume ió everyday for 4 weeks. Each sachet contains 4.5 g inulin and 6 g total fibre. Participants will consume one sachet daily in week 1 to allow acclimatisation, increasing to two sachets daily in weeks 2-4. Sachets are diluted in 500 mL of water and consumed with lunch and dinner.

Primary outcomes

  1. Fasting Plasma Glucose

    Time frame: Baseline and 4 weeks (end of intervention).

    Change in fasting plasma glucose measured from venous blood samples.

Secondary outcomes

  1. Anthropometric Measurements

    Time frame: Baseline and 4 weeks (end of intervention).

    Change in body fat percentage measured using standardised clinical methods.

  2. HbA1c (Glycated Haemoglobin)

    Time frame: Baseline and 4 weeks (end of intervention).

    Change in HbA1c as an exploratory marker of glycaemic control (interpretation is limited due to the short 4-week intervention duration).

  3. Inflammatory Markers

    Time frame: Baseline and 4 weeks (end of intervention).

    Change in circulating inflammatory markers associated with metabolic risk

  4. Gut Microbiota Composition

    Time frame: Baseline and 4 weeks (end of intervention).

    Changes in gut microbiota diversity and composition assessed via stool samples and 16S rRNA sequencing.

  5. Gastrointestinal Symptoms

    Time frame: Baseline and 4 weeks (end of intervention).

    Changes in self-reported gastrointestinal symptoms (score max 10 and less of 1) including stool frequency and consistency (Bristol Stool Scale), bloating, abdominal pain, and flatulence.

  6. Dietary Intake

    Time frame: Baseline and 4 weeks (end of intervention).

    Change in habitual dietary intake assessed using 4-day food records at baseline and after 4 weeks.

Study contacts

Contact information is provided by the study sponsor or research team.

ADELE COSTABILE, Prof

CONTACT

[email protected]

02083923571 ext. 3571

Savriniso Nazarova-Lewis, Master

CONTACT

[email protected]

07535721482

Sponsors and collaborators

Lead sponsor

University of Roehampton

Other

Registry information

Official study title

Improving Glucose Control Through Prebiotic Gut Health Drink in Postmenopausal Women

Acronym: BALANCE

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 4, 2026
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.